Supplements for Inflammation-Related Symptoms

A grey-market research peptide with NO completed human trials — every efficacy result below is from mice, rats, or cells. KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-melanocyte-stimulating hormone (α-MSH), and it carries α-MSH's anti-inflammatory activity without the pigment-inducing effect. In mouse and rat models of ulcerative colitis it consistently reduces gut inflammation, and reviews flag related melanocortin tripeptides as candidates for skin-wound healing. But KPV has never been tested in a completed human efficacy trial, it is not an approved drug or a lawful dietary supplement, and it is sold online as an unregulated research chemical with no quality control. Its human dosing, route, and long-term safety are unknown. This entry exists to inform, not to recommend.

A synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) reproducing the active site of the thymic hormone thymopoietin. Unlike grey-market peptides, thymopentin was a genuinely registered immunomodulator drug — marketed as Timunox in Italy and widely used in China — so it has real Western randomized trials behind it, not just anecdote. The strongest data are small placebo-controlled RCTs in active rheumatoid arthritis from the 1980s (Lancet, German multicentre) showing short-lived symptomatic improvement, and a 352-patient double-blind HIV trial where it modestly delayed disease progression. But the evidence is old, heterogeneous, and short-duration; benefits faded weeks after stopping; it failed as a vaccine adjuvant in at least one trial; and it is NOT an FDA-approved drug or a dietary supplement. Modern meta-analyses pooling Chinese adjuvant-therapy trials (tuberculosis, lung cancer) report benefits but are dominated by low-quality, unblinded studies. Treat this as a real but weakly-evidenced legacy immunomodulator, not a proven supplement.

An injectable anti-interleukin-1β monoclonal antibody (Ilaris), approved for rare periodic fever syndromes. Famous for the landmark CANTOS trial — the first proof that lowering inflammation alone (without touching lipids) cuts cardiovascular events, validating the 'inflammaging' hypothesis. But CANTOS showed NO all-cause-mortality benefit and MORE fatal infections, and the follow-up cancer trials failed. An extremely expensive prescription biologic, not a supplement.

An ancient anti-inflammatory drug (from autumn crocus) for gout and familial Mediterranean fever, now studied as a geroprotector targeting 'inflammaging.' Randomized trials (LoDoCo2, COLCOT) show low-dose colchicine reduces cardiovascular events in coronary disease — proof that dampening chronic inflammation has real outcome benefit. Lifespan itself is unproven. A prescription drug used off-label, not a supplement.

A prescription, highly-purified ethyl ester of EPA (Vascepa) — NOT a fish-oil supplement. At 4 g/day it lowers triglycerides and, in the REDUCE-IT trial of statin-treated high-risk patients, cut major cardiovascular events ~25%. Honest caveats: the mechanism of benefit is debated (the trial's mineral-oil comparator may have inflated the effect), it modestly raises atrial fibrillation and bleeding risk, and OTC omega-3/fish-oil supplements did NOT show the same benefit. Prescription drug, not a supplement.

An opioid-antagonist drug (naltrexone) taken off-label at very low doses (~1.5–4.5 mg) for chronic pain, fibromyalgia, and autoimmune/inflammatory conditions. The leading idea is that a brief nightly opioid-receptor blockade triggers a rebound rise in endorphins and dampens glial/TLR4 inflammation. Human trials are mostly small pilots with mixed results — a real but preliminary signal in fibromyalgia, weaker elsewhere. A prescription drug used off-label, not a supplement, and not a proven longevity drug.